Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2021-06-10 Regulatory Filings
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
PR - PHN agreement Fresenius Kaby Germany
Regulatory Filings Classification · 1% confidence The document is a formal announcement dated June 10, 2021, identified by the header 'Informazione Regolamentata' (Regulated Information) and the 'Oggetto' (Subject) being 'PR - PHN agreement Fresenius Kaby Germany'. The content details a new exclusive distribution agreement for SiderAL products in Germany. This type of announcement, concerning a significant business development (a distribution contract), is typically classified as a general regulatory filing or a specific business update. Since there is no specific category for 'Distribution Agreement' and it is not a standard financial report (10-K, IR, ER), nor a management change (MANG) or capital event (CAP/SHA), it fits best under the general Regulatory Filings category (RNS) or potentially a specific business/transaction category if one were available. Given the options, RNS serves as the best general regulatory announcement fallback for material, non-standard financial news. The document structure strongly suggests a press release format filed with a regulator.
2021-06-10 English
CS - PHN accordo con Fresenius Kabi Germania
Regulatory Filings Classification · 1% confidence The document is an official communication from Pharmanutra S.p.A. dated June 10, 2021, identified by the header "Informazione Regolamentata n. 20106-33-2021" and the type "REGEM". The subject ("Oggetto") is "CS - PHN accordo con Fresenius Kabi Germania" (Press Release - PHN agreement with Fresenius Kabi Germany). The content details a new exclusive distribution agreement for SiderAL® products in Germany. This format, which announces a significant business event (a partnership/distribution deal) via a formal regulatory channel, aligns best with a general Regulatory Filing or a specific announcement type. Since there is no specific code for 'Business Development Announcement' or 'Partnership Agreement', and it is a formal communication released through regulatory channels (indicated by the metadata structure typical of CONSOB/Borsa Italiana filings), it falls under the general regulatory announcement category. Given the options, 'RNS' (Regulatory Filings - General regulatory announcements and fallback category) is the most appropriate fit for this type of formal, market-moving press release that isn't a standard financial report (10-K, IR, ER) or a specific corporate action notice (DIV, SHA). The document length (6301 chars) is substantial enough to be the primary announcement, not just a brief notice of publication (RPA).
2021-06-10 Italian
PR - PHN sales figures may 07062021
Earnings Release Classification · 1% confidence The document is a press release from PharmaNutra S.p.A. dated June 7, 2021, announcing the 'SALES FIGURES FOR MAY 2021'. It details monthly sales volume, growth percentages compared to the previous year, and includes commentary from the CEO. This content aligns perfectly with an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only). It is not a comprehensive quarterly report (IR) or the full Annual Report (10-K). The document structure is typical of a press release announcing financial performance highlights. Q2 2021
2021-06-07 English
CS - PHN dati vendite maggio 07062021
Earnings Release Classification · 1% confidence The document is a formal communication identified by the header "Informazione Regolamentata" (Regulated Information) and is dated June 7, 2021. The subject line is "CS - PHN dati vendite maggio 07062021" (CS - PHN May sales data 07062021). The content explicitly details the company's sales figures for May 2021, noting a 36% increase and achieving the best monthly performance in the Group's history. This is a concise announcement of periodic financial performance highlights, not the full comprehensive report (like an IR or 10-K). Therefore, it fits the definition of an Earnings Release (ER). The document is short and primarily serves to release key figures quickly. Q2 2021
2021-06-07 Italian
PR - PHN Publication of minutes of Shareholders' Meeting 26 04 2021
Report Publication Announcement Classification · 1% confidence The document is a regulatory announcement (Informazione Regolamentata) from Pharmanutra S.p.A. dated May 26, 2021. The subject line explicitly states: 'PR - PHN Publication of minutes of Shareholders' Meeting 26 04 2021'. The body confirms this, stating that the 'notice of Shareholders' Meeting held on 26 April 2021 is available to the public' and directs readers to where the minutes can be found. Since the document itself is an announcement about the availability of the minutes (a report/document), and not the minutes themselves, it fits the definition of a Report Publication Announcement (RPA). The document length (4044 chars) is also consistent with a short announcement rather than a full report.
2021-05-26 English
CS - PHN Pubblicazione del verbale dell'assemblea del 26 04 2021
AGM Information Classification · 1% confidence The document is a short regulatory announcement (Informazione Regolamentata) dated May 26, 2021. The subject ('Oggetto') explicitly states: 'CS - PHN Pubblicazione del verbale dell'assemblea del 26 04 2021' (Publication of the minutes of the Shareholders' Meeting of April 26, 2021). The body text confirms this, stating that the minutes ('verbale') of the Shareholders' Meeting are available to the public. Since this is an announcement about the publication of meeting minutes, and not the minutes themselves or a proxy solicitation document, it fits the description of a Report Publication Announcement (RPA). It is too specific for the general RNS fallback, and while it relates to an AGM, the core action described is the *publication* of the minutes, not the meeting materials themselves (AGM-R) or the voting results (DVA). Given the short length and the explicit statement that the report is available elsewhere ('Vedi allegato' and details on where to find the minutes), RPA is the most appropriate classification based on Rule 2.
2021-05-26 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.